drugset / Trial / NCT04822584

Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

NCT04822584

Phase 2 Completed 49 enrolled University Hospital, Bordeaux
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this phase 2 study is to evaluate the effect and the safety of the combination of Baricitinib in combination with phototherapy in adult participants with non-segmental progressive vitiligo.

Timeline

Start
2021-07-16
Primary completion
2023-04-26
Completion
2023-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 4 mg Oral

Indications